Back

STAAR Surgical shares jump 7% after Stifel upgrade to Buy

Verifying
  • STAAR Surgical shares rose 7% after Stifel upgraded the company to Buy.
  • $31 target represents an increase from $28 under analyst Thomas Stephan’s revised recommendation.
  • STAAR is projected to post 11% annual revenue growth through 2028, versus 8% consensus.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.